摘要
目的探讨骨髓增生异常综合征(MDS)移植后应用地西他滨维持治疗的效果。方法收集2016年4月至2019年10月于郑州大学第一附属医院行异基因造血干细胞移植且在移植后给予小剂量地西他滨维持治疗的MDS患者7例,男5例,女2例,年龄15~43岁。7例患者移植前均予以地西他滨或联合小剂量阿糖胞苷、阿克拉霉素、粒细胞集落刺激因子方案治疗,移植前均达完全缓解状态,移植后地西他滨维持治疗56(31~78)d。回顾性分析其治疗效果。结果7例患者移植后均未复发,1例因急性肠道移植物抗宿主病死亡,6例随访至今,2例出现慢性轻度肝脏移植物抗宿主病,移植后中位随访时间12(3~30)个月。结论高危MDS患者移植后应用小剂量地西他滨可能改善移植后生存,但需进一步研究证实。
Objective To investigate the effect of decitabine maintenance treatment after transplantation of myelodysplastic syndrome(MDS).Methods Seven patients with MDS after allogeneic hematopoietic stem cell transplantation in the First Affiliated Hospital of Zhengzhou University from April 2016 to October 2019 and received low-dose decitabine maintenance transplantation were included,5 males and 2 females,aged 15 to 43 years.Seven patients were treated with decitabine or a combination of low-dose cytarabine,aclamycin,and granulocyte colony-stimulating factor regimens before transplantation,and they all achieved complete remission before transplantation,and decicabine was maintained for 56(31~78)days after tranplantation.The treatment results were analyzed retrospectively.Results None of the patients recurred after transplantation,1 case died of acute intestinal graft-versus-host disease,six cases were followed-up to date,and 2 case of chronic mild liver graft-versus-host disease,with a median follow-up of 12 months(3~30 months)after transplantation.Conclusions Low dose of decitabine could improve post-transplant survival in high-risk MDS patients,but further research is needed to confirm.
作者
王海琼
郭荣
谢新生
姜中兴
万鼎铭
刘延方
董振坤
刘佳
丁文稳
Wang Haiqiong;Guo Rong;Xie Xinsheng;Jiang Zhongxing;Wan Dingming;Liu Yanfang;Dong Zhenkun;Liu Jia;Ding Wenwen(Department of Hematology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中国实用医刊》
2020年第6期9-13,共5页
Chinese Journal of Practical Medicine
基金
国家自然科学基金(81070445)
河南省自然科学基金(182300410301)
河南省医学科技攻关计划(201403029)。
关键词
骨髓增生异常综合征
异基因造血干细胞移植
地西他滨
移植物抗宿主病
Myelodysplastic syndrome
Allogeneic hematopoietic stem cell transplantation
Decitabine
Graft versus host disease
